Skip to main content

Xtrana Wins $400K NIH Grant

NEW YORK, Aug. 29 – Xtrana has received a $400,000 Phase I NIH grant to develop nanofluidic nucleic acid preparation components, the company announced Wednesday.

The work will be done in collaboration with researchers at the University of New Mexico and Sandia National Laboratory.

The research builds on Broomfield, Colo.-based Xtrana’s Xtra Bind non-silica-based nucleic acid extraction technology. The application for the nanofluidic technology is to let users run assay panels for infectious diseases and other agents at the site of sample collection, the company said.

Xtrana develops, manufactures, markets test kits to assess and diagnose disorders of the blood and vascular system.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.